Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Pharmacol. 2006 Feb 15;531(1-3):282-4. Epub 2006 Jan 19.

Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.

Author information

  • 1Fundación IMABIS, Hospital Carlos Haya, Avenida Carlos Haya s/n, 7(a) Planta, Pabellón A, Málaga 29010, Spain.


Recent reports have described the presence of cannabinoid CB1 receptors in pancreatic islets. Here we show that administration of the endogenous cannabinoid anandamide or the selective cannabinoid CB1 receptor agonist Arachidonyl-2'-chloroethylamide (ACEA) results in glucose intolerance after a glucose load. This effect is reversed by the selective cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251). These results suggest that targeting cannabinoid CB1 receptors may serve as new therapeutic alternatives for metabolic disorders such as diabetes.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk